• 1
    LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996; 22: 67594.
  • 2
    Gustafsson R, Mannting F, Kazzam E, Waldenström A, Hällgren R. Cold-induced reversible myocardial ischaemia in systemic sclerosis. Lancet 1989; 8: 4759.
  • 3
    Gastaud M, Dolisi C, Bermon S, Gaudin P, Defauw G, Ardisson JL. Short-term effect of cold provocation on single-breath carbon monoxide diffusing capacity in subjects with and without Raynaud's phenomenon. Clin Exp Rheumatol 1995; 13: 61721.
  • 4
    Freedman R, Girgis R, Mayes MD. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J Rheumatol 1999; 26: 23868.
  • 5
    Freedman RR, Girgis R, Mayes MD. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J Rheumatol 2001; 28: 11921.
  • 6
    Anderson ME, Hollis S, Moore T, Jayson MIV, Herrick AL. Non-invasive assessment of vascular reactivity in forearm skin of patients with primary Raynaud's phenomenon and systemic sclerosis. Br J Rheumatol 1996; 35: 12818.
  • 7
    Anderson ME, Campbell F, Hollis S, Moore T, Jayson MIV, Herrick AL. Non-invasive assessment of digital vascular reactivity in patients with primary Raynaud's phenomenon and systemic sclerosis. Clin Exp Rheumatol 1999; 17: 4954.
  • 8
    La Civita L, Rossi M, Vagheginni G, Storino FA, Credido L, Pasero G, et al. Microvascular involvement in systemic sclerosis: laser Doppler evaluation of reactivity to acetylcholine and sodium nitroprusside by iontophoresis. Ann Rheum Dis 1998; 57: 525.
  • 9
    Flavahan NA, Flavahan S, Liu Q, Wu S, Tidmore W, Wiener CM, et al. Increased α2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000; 43: 188690.
  • 10
    Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998; 25: 3147.
  • 11
    Cotton SA, Herrick AL, Jayson MIV, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 1999; 189: 2738.
  • 12
    Andersen GN, Caidahl K, Kazzam E, Petersson A-S, Waldenström A, Mincheva-Nilsson L, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000; 43: 108593.
  • 13
    Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 1991; 34: 97883.
  • 14
    Kazzam E, Waldenström A, Hedner T, Hedner J, Caidahl K. Endothelin may be pathogenic in systemic sclerosis of the heart. Int J Cardiol 1997; 60: 319.
  • 15
    Gruschwitz MS, Hornstein OP, von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995; 38: 1849.
  • 16
    Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM, et al. Serial circulating adhesion molecule levels reflect disease activity in systemic sclerosis. Br J Rheumatol 1995; 34: 104854.
  • 17
    D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 42840.
  • 18
    Brinton TJ, Cotter B, Kailasam MT, Brown DL, Chio SS, O'Connor DT, et al. Development and validation of a noninvasive method to determine arterial pressure and vascular compliance. Am J Cardiol 1997; 80: 32330.
  • 19
    Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 11115.
  • 20
    Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 13149.
  • 21
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 22
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 23
    Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease: study of 593 patients. J Rheumatol 1989; 16: 32834.
  • 24
    Allen EV, Brown GE. Raynaud's disease: a critical review of minimal requisites for diagnosis. Am J Med Sci 1932; 183: 187200.
  • 25
    Silman A, Harrison M, Brennan P, for the Ad Hoc International Group on the Assessment of Disease Outcome in Scleroderma. Is it possible to reduce observer variability in skin score assessment of scleroderma? J Rheumatol 1995; 22: 127780.
  • 26
    Wennmalm Å, Benthin G, Edlund A, Jungersten L, Kieler-Jensen N, Lundin S, et al. Metabolism and excretion of nitric oxide in humans: an experimental and clinical study. Circ Res 1993; 73: 11217.
  • 27
    Wållberg-Jonsson S, Dahlen GH, Nilsson TK, Rånby M, Rantapää-Dahlqvist S. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 1993; 12: 31824.
  • 28
    Jensen-Urstad K, Rosfors S. A methodological study of arterial wall function using ultrasound technique. Clin Physiol 1997; 17: 55767.
  • 29
    Stucker M, Quinna S, Memmel U, Rochling A, Traupe M, Koster O, et al. Macroangiopathy of the upper extremities in progressive systemic sclerosis. Eur J Med Res 2000; 19: 295302.
  • 30
    Farrell AJ, Blake DR. Nitric oxide. Ann Rheum Dis 1996; 55: 720.
  • 31
    Lekakis J, Mavrikakis M, Papamichael C, Papazoglou S, Economou O, Scotiniotis I, et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J 1998; 136: 90512.
  • 32
    Lekakis J, Papamichael C, Mavrikakis M, Stamatelopoulos S. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilatation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol 1998; 82: 15557.
  • 33
    Yamashita T, Kawashima S, Ohashi Y, Ozaki M, Rikitake Y, Inoue N, et al. Mechanisms of reduced nitric oxide/cGMP-mediated vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. Hypertension 2000; 36: 97102.
  • 34
    Elkayam U, Mehra A, Shotan A, Osprzega E. Possible mechanisms of nitrate tolerance. Am J Cardiol 1992; 70: 49G53G; discussion 53G–54G.
  • 35
    Packer M. What causes tolerance to nitroglycerin? The 100 year old mystery continues. J Am Coll Cardiol 1990; 16: 9325.
  • 36
    Rydell EL, Axelsson KL. Adrenaline toxicity in mice: sensitization of alpha 1 adrenoceptors by nitroglycerin. Acta Pharmacol Toxicol (Copenh) 1984; 55: 737.
  • 37
    Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A 1995; 92: 52448.
  • 38
    Ziegler T, Silacci P, Harrison VJ, Hayoz D. Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. Hypertension 1998; 32: 3515.
  • 39
    Kahaleh B, Fan P-S. Down regulation of nitric oxide synthase gene in microvascular endothelial cells from lesional scleroderma: assessment by quantitative RT-PCR and possible role for cytotoxic T-cells [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S277.